Progression of Cutaneous T-Cell Lymphoma after dupilumab: Case review of 7 patients

Published: 19 March 2020| Version 1 | DOI: 10.17632/79dp7449jw.1
Maria Espinosa,
Morgan Nguyen,
Amaia Saenz Aguirre,
Maria Estela Martinez-Escala,
Jane Kim,
Christina Walker,
David Pontes,
Jonathan Silverberg,
Jaehyuk Choi,
Barbara Pro,
Laura Pincus,
Joan Guitart,
Xiaolong Zhou


Supplement 1: Report of Cases Seven patients were prescribed dupilumab for chronic recalcitrant presumed AD (cases 1-4), or as an off-label treatment for patients with MF and severe pruritus (cases 5-7). In all 7 patients, the standard dosing regimen for dupilumab was followed (600mg loading dose, followed by 300mg every 2 weeks subcutaneously). Case vignettes and photographs found below.